Search Within

Ingo K Mellinghoff

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (29)
  3. Research Letter (3)
  4. Conference Paper (1)
  5. Correspondence (1)
Groups
  1. Department of Pathology and Laboratory Medicine (69)
  2. GSK Faculty (69)
  3. Human Oncology and Pathogenesis Program (69)
  4. Tow Center for Developmental Oncology (TCDO) (69)
  5. Sloan Kettering Institute Postdocs (33)
  6. Radiology, Department of (32)

More Groups

People
  1. Tejus Bale (35)
  2. Alexandra Miller (30)
  3. Marc Rosenblum (27)
  4. Maria Arcila (22)
  5. Robert Young (22)
  6. Michael Berger (20)

More People

Years
  1. 2024 (13)
  2. 2023 (14)
  3. 2022 (7)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (7)

More Years

Publications
  1. Neuro-Oncology (23)
  2. Journal of Clinical Oncology (5)
  3. Clinical Cancer Research (4)
  4. Journal of Neuropathology and Experimental Neurology (4)
  5. Cancer Discovery (3)
  6. Nature Genetics (3)

More Publications

Publishers
  1. Oxford University Press (27)
  2. American Association for Cancer Research (9)
  3. Nature Publishing Group (9)
  4. American Society of Clinical Oncology (7)
  5. BioMed Central Ltd. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (69)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improved characterization of molecular phenotypes in breast lesions using 18F-FDG PET image homogeneity
    Conference Paper

    Cao, K.; Bhagalia, R.; Sood, A.; Brogi, E.; Mellinghoff, I. K.; Larson, S. M.
    SPIE (2015)

    Fulltext@MSK | Save
  • Is next generation sequencing (NGS) ready for routine clinical practice in gliomas? Results of a prospective study utilizing the MSK-IMPACT assay
    Meeting Abstract

    Omuro, A. M. P.; Zehir, A.; Cheng, D. T.; Berger, M. F.; Hyman, D. M.; Solit, D. B.; Baselga, J.; Ladanyi, M.; Arcila, M. E.; Hameed, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth
    Journal Article

    Ran, L.; Sirota, I.; Cao, Z.; Murphy, D.; Shukla, S.; Xie, Y.; Kaufmann, M. C.; Gao, D.; Zhu, S.; Rossi, F.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Application of a multiplexed fluorescence microscopy method (MultiOmyx (TM)) to dissect proteomic biomarkers of (18)F-fluorodeoxy-glucose ((18)FDG) uptake in breast cancer
    Meeting Abstract

    Sood, A.; Miller, A. M.; Ginty, F.; McDonough, E.; Sui, Y. X.; Bordwell, A.; Li, Q.; Kaanumalle, S.; Pang, Z. Y.; Torres, F.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
    Journal Article

    Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E.; more...
    Science (2013)

    Fulltext@MSK | Save
  • Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
    Journal Article

    Morris, L. G. T.; Kaufman, A. M.; Gong, Y.; Ramaswami, D.; Walsh, L. A.; Turcan, S.; Eng, S.; Kannan, K.; Zou, Y.; Peng, L.; more...
    Nature Genetics (2013)

    Fulltext@MSK | Save
  • Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies
    Journal Article

    Veeriah, S.; Taylor, B. S.; Meng, S.; Fang, F.; Yilmaz, E.; Vivanco, I.; Janakiraman, M.; Schultz, N.; Hanrahan, A. J.; Pao, W.; more...
    Nature Genetics (2010)

    Fulltext@MSK | Save
  • The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
    Journal Article

    Veeriah, S.; Brennan, C.; Meng, S.; Singh, B.; Fagin, J. A.; Solit, D. B.; Paty, P. B.; Rohle, D.; Vivanco, I.; Chmielecki, J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save